Literature DB >> 32989047

Incidence of retinopathy of prematurity in Germany: evaluation of current screening criteria.

Petra P Larsen1, Andreas Müller2, Wolf A Lagrèze3, Frank G Holz1, Andreas Stahl4, Tim U Krohne5,6.   

Abstract

OBJECTIVE: To evaluate current screening criteria for retinopathy of prematurity (ROP) by investigating the incidence of ROP requiring treatment in infants with gestational age (GA) ≥30 weeks or postmenstrual age (PMA) <32 weeks in Germany.
METHODS: Three patient databases were analysed, that is, the German Quality Assurance Procedure in Neonatology (years 2011-2017; n=52 461 infants screened for ROP, 1505 infants treated for ROP), the German Retina.net ROP Registry (years 2011-2018; n=281 treated infants) and the ROP screening programme of two German university hospitals (years 2012-2016; n=837 screened infants).
RESULTS: In the analysed cohorts, infants with GA ≥30 weeks represented 33.1%-38.5% of the screening populations but only 1.40%-1.42% of the cases requiring ROP treatment. In a cohort of 281 infants treated for ROP, all 4 infants with GA ≥30 weeks had additional risk factors for ROP including prolonged oxygen supplementation and/or significant comorbidities. Five infants (1.8%) were treated at 32 weeks PMA and none at PMA <32 weeks.
CONCLUSIONS: In the investigated cohorts, preterm infants with GA ≥30 weeks carried a very low or no risk for developing treatment-requiring ROP unless additional risk factors were present, and no treatment was performed earlier than 32 weeks PMA. These findings are of relevance for the ongoing re-evaluation of ROP screening criteria. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epidemiology; neonatology; ophthalmology

Mesh:

Year:  2020        PMID: 32989047     DOI: 10.1136/archdischild-2020-319767

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  5 in total

1.  Retrospective validation of the postnatal Growth and Retinopathy of Prematurity (G-ROP) criteria in a Swiss cohort.

Authors:  Nithursa Vinayahalingam; Jane McDougall; Olaf Ahrens; Andreas Ebneter
Journal:  BMC Ophthalmol       Date:  2022-01-10       Impact factor: 2.209

2.  Frequency of retinopathy of prematurity (ROP) in infants screened for ROP: two years follow-up results of a single center in Turkey.

Authors:  Adem Ugurlu
Journal:  Biomedicine (Taipei)       Date:  2021-09-01

3.  Long use of continuous positive airway pressure protects against the development of treatment-requiring retinopathy of prematurity.

Authors:  Shutaro Suga; Yuki Kyono; Takumi Kido; Ruka Nakasone; Shinya Abe; Mariko Ashina; Kandai Nozu; Kazumichi Fujioka
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.379

4.  [Epidemiology and treatment of retinopathy of prematurity. The Hannover data in the Retina.net ROP registry from 2001-2017].

Authors:  Stella H Akman; Johanna M Pfeil; Andreas Stahl; Stephanie Ehlers; Carolin Böhne; Bettina Bohnhorst; Carsten Framme; Dorothee Brockmann; Anna Bajor; Christina Jacobsen; Karsten Hufendiek; Amelie Pielen
Journal:  Ophthalmologe       Date:  2021-11-22       Impact factor: 1.174

Review 5.  Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?

Authors:  Anne Klotzsche-von Ameln; David Sprott
Journal:  Pflugers Arch       Date:  2022-05-07       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.